Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 45,20 € (+21,77 %). La mediana es de 46,19 € (+24,43 %).
| Comprar |
3 |
| Mantener |
0 |
| Vender |
0 |
Noticias Ir al feed de noticias
LB Pharmaceuticals appoints Dr. Susan G. Kozauer as chief medical officer
LB Pharmaceuticals has appointed Dr. Susan G. Kozauer as chief medical officer. Kozauer brings more than 20 years of experience in developing neuropsychiatric drugs, most recently serving as senior vice president and head of clinical development at Centessa Pharmaceuticals. The appointment comes ahead of the expected topline results from the Phase 3 NOVA‑2 trial of LB‑102 for schizophrenia, anticipated in the first half of 2027. Kozauer holds a degree from Cornell, an MD from George Washington University, and completed a psychiatry residency at Georgetown University Hospital. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | -84,99 mil | - |
| Beneficio neto | -45,22 M | 947,33 % |
| EBITDA | -47,16 M | 965,48 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1063,88 M € |
Número de acciones | 28,68 M |
Máximo/mínimo de 52 semanas | 43,71 € - 11,64 € |
| Dividendos | No |
Beta | 0,42 |
Ratio P/E | -14,33 |
Ratio PEG | -0,08 |
Ratio P/B | 3,86 |
Ratio P/S | 0,00 |
Perfil de la empresa
Biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapien für neuropsychiatrische Erkrankungen (z. B. Schizophrenie, bipolare Depression) entwickelt. Hauptkandidat ist LB-102, ein methyliertes Derivat von Amisulprid.
| Nombre | LB Pharmaceuticals |
| CEO | Heather D. Turner |
| Sitio web | |
| Salida a bolsa | 11/09/2025 |
| Empleados | 49 |
